Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy
Wei Ni, Swati Garg, Basudev Chowdhury, Martin Sattler, Dana Sanchez, Chengcheng Meng, Taisei Akatsu, Katherine A. Donovan, Jun Qi, Michelle Y. Wang, Cara Ann Starnbach, Xiaoxi Liu, Maria Tarazona Guzman, Wei Pin Teh, Richard Stone, James D. Griffin, Sara Buhrlage, Ellen Weisberg
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMultiple Myeloma Research and Treatments · Signaling Pathways in Disease
Main text
(Molecular Therapy: Oncology 33, 200952; March 2025)
In the originally published version of the article, a short title (“Synergy between CARM1 inhibition and IMIDs”) under the actual title was merged with the actual title. The correct title for this paper is “Dual CARM1- and IKZF3-targeting: a novel approach to multiple myeloma therapy.” The short title was included by accident, and unfortunately, this mistake was not caught during the proof stage. The authors and editors apologize for this mistake.